• Consensus Rating: Buy
  • Consensus Price Target: $5.40
  • Forecasted Upside: 300.00 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$1.35
▼ -0.05 (-3.57%)

This chart shows the closing price for OCGN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Ocugen Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OCGN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OCGN

Analyst Price Target is $5.40
▲ +300.00% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Ocugen in the last 3 months. The average price target is $5.40, with a high forecast of $8.00 and a low forecast of $3.50. The average price target represents a 300.00% upside from the last price of $1.35.

This chart shows the closing price for OCGN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 5 polled investment analysts is to buy stock in Ocugen. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/18/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/16/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/15/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/15/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/13/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/11/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/10/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/10/2022

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/23/2022MizuhoInitiated CoverageBuy$5.00Low
8/15/2022HC WainwrightLower TargetBuy$7.00 ➝ $6.00Low
6/15/2022Roth CapitalReiterated RatingNeutral ➝ Buy$8.00High
6/2/2022Cantor FitzgeraldInitiated CoverageOverweight$4.50High
5/9/2022Chardan CapitalLower TargetNeutral ➝ Neutral$4.00 ➝ $3.50High
4/11/2022Chardan CapitalReiterated RatingNeutralHigh
3/29/2022Chardan CapitalLower Target$4.50 ➝ $4.00High
2/28/2022HC WainwrightLower TargetBuy$10.00 ➝ $8.00High
11/8/2021Noble FinancialReiterated RatingBuy$15.00Low
11/2/2021Roth CapitalReiterated RatingHold$6.00High
11/2/2021Cantor FitzgeraldReiterated RatingNeutral$4.00High
10/28/2021Noble FinancialReiterated RatingBuy$15.00Low
8/9/2021HC WainwrightReiterated RatingBuy$10.00Low
7/26/2021Noble FinancialInitiated CoverageBuy$6.80Medium
6/11/2021HC WainwrightLower TargetBuy$12.00 ➝ $10.00High
6/10/2021Roth CapitalDowngradeBuy ➝ Neutral$10.00 ➝ $6.00High
6/10/2021Chardan CapitalLower TargetNeutral$8.00 ➝ $4.50N/A
5/13/2021Cantor FitzgeraldReiterated RatingOverweight ➝ Neutral$15.00 ➝ $11.00N/A
5/10/2021Chardan CapitalLower TargetNeutral$13.00 ➝ $8.00High
5/7/2021Cantor FitzgeraldDowngradeOverweight ➝ Neutral$11.00High
3/4/2021Roth CapitalBoost TargetBuy$9.00 ➝ $10.00Medium
2/9/2021Chardan CapitalDowngradeBuy ➝ NeutralLow
2/4/2021HC WainwrightUpgradeNeutral ➝ Buy$4.50Low
2/3/2021Roth CapitalBoost TargetPositive ➝ Buy$1.00 ➝ $8.00High
2/3/2021Cantor FitzgeraldBoost TargetPositive ➝ Overweight$1.00 ➝ $4.00Medium
11/16/2020Roth CapitalInitiated CoverageBuy$1.00Low
11/9/2020HC WainwrightReiterated RatingHoldHigh
10/9/2020Cantor FitzgeraldInitiated CoverageOverweight$1.00High
8/17/2020HC WainwrightReiterated RatingHoldHigh
8/16/2020Chardan CapitalReiterated RatingBuy$0.70High
6/3/2020Chardan CapitalLower TargetBuy$2.00 ➝ $0.70Medium
6/1/2020HC WainwrightDowngradeBuy ➝ NeutralHigh
5/17/2020Chardan CapitalReiterated RatingBuy$2.00Low
3/30/2020Chardan CapitalReiterated RatingBuy$2.00High
12/20/2019HC WainwrightInitiated CoverageBuy$1.25High
11/27/2019Chardan CapitalInitiated CoverageBuy$2.00High
(Data available from 12/10/2017 forward)

News Sentiment Rating

1.02 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 9 very positive mentions
  • 27 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
5/14/2022
  • 4 very positive mentions
  • 15 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
6/13/2022
  • 4 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
7/13/2022
  • 5 very positive mentions
  • 14 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/12/2022
  • 11 very positive mentions
  • 11 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
9/11/2022
  • 4 very positive mentions
  • 15 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/11/2022
  • 4 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/10/2022
  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/10/2022

Current Sentiment

  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.
Ocugen logo
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.
Read More

Today's Range

Now: $1.35
Low: $1.34
High: $1.42

50 Day Range

MA: $1.62
Low: $1.35
High: $1.87

52 Week Range

Now: $1.35
Low: $1.32
High: $5.78

Volume

3,060,888 shs

Average Volume

7,523,564 shs

Market Capitalization

$295.50 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.96

Frequently Asked Questions

What sell-side analysts currently cover shares of Ocugen?

The following Wall Street analysts have issued research reports on Ocugen in the last twelve months: Cantor Fitzgerald, Chardan Capital, HC Wainwright, Mizuho, and Roth Capital.
View the latest analyst ratings for OCGN.

What is the current price target for Ocugen?

5 Wall Street analysts have set twelve-month price targets for Ocugen in the last year. Their average twelve-month price target is $5.40, suggesting a possible upside of 300.0%. Roth Capital has the highest price target set, predicting OCGN will reach $8.00 in the next twelve months. Chardan Capital has the lowest price target set, forecasting a price of $3.50 for Ocugen in the next year.
View the latest price targets for OCGN.

What is the current consensus analyst rating for Ocugen?

Ocugen currently has 1 hold rating and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe OCGN will outperform the market and that investors should add to their positions of Ocugen.
View the latest ratings for OCGN.

What other companies compete with Ocugen?

How do I contact Ocugen's investor relations team?

Ocugen's physical mailing address is 5 GREAT VALLEY PARKWAY V, MALVERN PA, 19355. The company's listed phone number is (484) 328-4701 and its investor relations email address is [email protected] The official website for Ocugen is ocugen.com. Learn More about contacing Ocugen investor relations.